Kelli Dumm, MD
Internal Medicine · Charleston, WVNPI 1760461164
Payments from drug & device makers
Across 145 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$881
- AbbVie$406
- Pfizer$191
- Lilly USA, LLC$151
- GSK$111
- Sumitomo Pharma America, Inc.$87
- plus $702 from 21 others
What the payments were for
- Food & beverage$2,531100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $881 |
| AbbVie(2 entities) | 20 | $406 |
| Pfizer | 10 | $191 |
| Lilly USA, LLC | 8 | $151 |
| GSK | 7 | $111 |
| Sumitomo Pharma America, Inc. | 4 | $87 |
| AstraZeneca | 6 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Bayer | 4 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Abbott | 2 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $46 |
| Merck | 3 | $45 |
| Dexcom, Inc. | 2 | $35 |
| Shire North American Group Inc | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Philips North America LLC | 1 | $25 |
| Neos Therapeutics, LP | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
| Amgen | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Aytu Biopharma, Inc. | 1 | $11 |
How this compares
$2,531 in reported general payments places this provider in the 80th percentile of 573 internal medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $171,445 |
| EliquisApixaban | 171 | $151,797 |
| JardianceEmpagliflozin | 102 | $118,074 |
| JanuviaSitagliptin Phosphate | 120 | $109,028 |
| MounjaroTirzepatide | 44 | $66,189 |
| XareltoRivaroxaban | 55 | $51,480 |
| TrulicityDulaglutide | 22 | $28,111 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $26,130 |
| LinzessLinaclotide | 28 | $23,054 |
| FarxigaDapagliflozin Propanediol | 14 | $17,399 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $14,948 |
| MyrbetriqMirabegron | 23 | $12,466 |
| EntrestoSacubitril/Valsartan | 14 | $11,578 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $11,116 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 506 | $10,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $881 | $171,445132 claims |
| PfizerEliquis | $191 | $151,797171 claims |
| MerckJanuvia, Belsomra, Dulera | $45 | $117,969144 claims |
| Lilly USA, LLCMounjaro, Trulicity | $151 | $94,30066 claims |
| Johnson & JohnsonXarelto | $30 | $51,48055 claims |
| AbbVieLinzess, Synthroid | $406 | $32,615143 claims |
| AstraZenecaFarxiga, Symbicort | $79 | $24,15642 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $12,46623 claims |
| GSKBreo Ellipta | $111 | $6,68617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Charleston
- William ChapmanCharleston$1.7M
- Phillip TriplettCharleston$17K
- Roy BowdenCharleston$14K
- Richard CapitoCharleston$11K
- Ghali Ibrahim-BachaCharleston$9K
- Jack KinderCharleston$8K
- Bradley HenryCharleston$8K
- Brijal PatelCharleston$8K
- William JeffreyCharleston$7K
- Said HajouliCharleston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.